Literature DB >> 35422921

Characteristics of pathogenic bacteria in intra-abdominal infection and risk factors for septic shock in patients with liver cirrhosis.

Yan Yan1, Qiaoxia Ye1, Liguan Liu1.   

Abstract

OBJECTIVE: To explore the characteristics of pathogenic bacteria in intra-abdominal infection and the risk factors for septic shock in patients with liver cirrhosis.
METHODS: This retrospective study analyzed the clinical data of patients with cirrhosis admitted to the Department of Infectious Diseases of the 910th Hospital of Chinese People's Liberation Army, who were divided into an intra-abdominal infection group (n=145) and non-infection group (n=100). We analyzed the risk factors for intra-abdominal infection in patients with liver cirrhosis, and further conducted bacterial culture for patients with intra-abdominal infection to investigate the distribution of pathogenic bacteria and analyzed the risk factors for septic shock.
RESULTS: Multivariate regression analysis found that age (P=0.005), length of hospital stay (P=0.024), invasive operation (P=0.002), and hypoproteinemia (P=0.026) were risk factors for intra-abdominal infection in patients with cirrhosis. 65 of the 145 patients with intra-abdominal infection were tested to be pathogen-positive, with a positivity rate of 44.83%. A total of 118 strains were isolated from the samples of 65 patients with positive test results. Among the 118 strains, 74 of them were gram-negative bacteria (62.71%), 41 were gram-positive bacteria (34.75%), and 3 were fungus (2.54%). Multivariate regression analysis found that age (P=0.003), length of stay (P=0.001), invasive operations (P=0.024) and hypoproteinemia (P=0.001) were all risk factors for septic shock in patients with liver cirrhosis combined with intra-abdominal infection.
CONCLUSION: Age, length of hospital stay, invasive operation, and hypoproteinemia are risk factors for intra-abdominal infection and septic shock in patients with cirrhosis, and gram-negative bacteria are the main pathogens in associated intra-abdominal infection. AJTR
Copyright © 2022.

Entities:  

Keywords:  Liver cirrhosis; characteristics of pathogenic bacteria; intra-abdominal infection; risk factors; septic shock

Year:  2022        PMID: 35422921      PMCID: PMC8991129     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  16 in total

1.  Clostridium difficile colonization and infection in patients with hepatic cirrhosis.

Authors:  Dong Yan; Yunbo Chen; Tao Lv; Yandi Huang; Jiezuan Yang; Yongtao Li; Jianrong Huang; Lanjuan Li
Journal:  J Med Microbiol       Date:  2017-09-25       Impact factor: 2.472

2.  Pathogen profile and drug resistance analysis of spontaneous peritonitis in cirrhotic patients.

Authors:  Yong-Tao Li; Cheng-Bo Yu; Jian-Rong Huang; Zheng-Ji Qin; Lan-Juan Li
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

3.  Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial.

Authors:  Thierry Thévenot; Christophe Bureau; Frédéric Oberti; Rodolphe Anty; Alexandre Louvet; Aurélie Plessier; Marika Rudler; Alexandra Heurgué-Berlot; Isabelle Rosa; Nathalie Talbodec; Thong Dao; Violaine Ozenne; Nicolas Carbonell; Xavier Causse; Odile Goria; Anne Minello; Victor De Ledinghen; Roland Amathieu; Hélène Barraud; Eric Nguyen-Khac; Claire Becker; Thierry Paupard; Danielle Botta-Fridlung; Naceur Abdelli; François Guillemot; Elisabeth Monnet; Vincent Di Martino
Journal:  J Hepatol       Date:  2014-11-21       Impact factor: 25.083

4.  Risk factor of community-onset spontaneous bacterial peritonitis caused by fluoroquinolone-resistant Escherichia coli in patients with cirrhosis.

Authors:  Jungok Kim; Cheol-In Kang; Eun-Jeong Joo; Young Eun Ha; Sun Young Cho; Geum-Youn Gwak; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song
Journal:  Liver Int       Date:  2013-11-24       Impact factor: 5.828

5.  Improved prognosis of septic shock in patients with cirrhosis: a multicenter study*.

Authors:  Arnaud Galbois; Philippe Aegerter; Patricia Martel-Samb; Chantal Housset; Dominique Thabut; Georges Offenstadt; Hafid Ait-Oufella; Eric Maury; Bertrand Guidet
Journal:  Crit Care Med       Date:  2014-07       Impact factor: 7.598

Review 6.  Immune dysfunction in cirrhosis.

Authors:  Nora Sipeki; Peter Antal-Szalmas; Peter L Lakatos; Maria Papp
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

7.  Platypnea-orthodeoxia Syndrome in a Patient with Cryptogenic Liver Cirrhosis: An Elusive Cause of Hypoxemia.

Authors:  Edward Rojas; Adem Aktas; Hardik Parikh; Umar S Khawaja; Kathleen Pergament
Journal:  Cureus       Date:  2019-01-08

8.  In HCV-related liver cirrhosis, local pulse wave velocity increases and in decompensated patients correlates with poorer survival.

Authors:  Chien-Hao Huang; Lung-Sheng Wu; Wen-Juei Jeng; Yu-Fu Cheng; Yu-Shien Ko; I-Shyan Sheen; Chun-Yen Lin
Journal:  PLoS One       Date:  2019-03-19       Impact factor: 3.240

9.  Spontaneous bacteremia and spontaneous bacterial peritonitis share similar prognosis in patients with cirrhosis: a cohort study.

Authors:  Sebastián Marciano; Melisa Dirchwolf; Carla S Bermudez; Natalia Sobenko; Leila Haddad; Federico Genre Bert; Laura Barcán; Astrid Smud; Maria Lourdes Posadas-Martínez; Diego Giunta; Adrián Gadano
Journal:  Hepatol Int       Date:  2017-12-09       Impact factor: 6.047

10.  Decreased macrophage inflammatory protein (MIP)-1α and MIP-1β increase the risk of developing nasopharyngeal carcinoma.

Authors:  Meng-Jie Yang; Jie Guo; Yan-Fang Ye; Sui-Hong Chen; Li-Xia Peng; Chu-Yang Lin; Ting Hu; Shang-Hang Xie; Chuan-Bo Xie; Qi-Hong Huang; Yu-Qiang Lu; Qing Liu; Chao-Nan Qian; Su-Mei Cao
Journal:  Cancer Commun (Lond)       Date:  2018-04-03
View more
  1 in total

1.  Linezolid in the treatment of severe intraabdominal infection: A STROBE-compliant retrospective study.

Authors:  Deyuan You; Yuexiang Su; Xuri Sun; Jianbao Wang; Yuxin Zheng; Yuqi Liu
Journal:  Medicine (Baltimore)       Date:  2022-08-19       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.